Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
ALN-TTR02 (patisiran) administered by intravenous (IV) infusion
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial -
ALN-TTRSC (revusiran) for subcutaneous administration
Alnylam Netherlands B.V.
TTR-mediated Amyloidosis
1 trial -
ALXN 2040, Placebo matching ALXN2040
Alexion Europe SAS
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
1 trial -
ALXN 2050, ALXN2050 Placebo Tablets
Alexion Europe SAS
Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
1 trial -
ALXN2420, OCTREOTIDE ACETATE, OCTREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, matching placebo for ALXN2420, LANREOTIDE ACETATE, OCTREOTIDE ACETATE
Alexion Europe SAS
Acromegaly
1 trial -
AMGLIDIA 6 mg/mL oral suspension
Pari Pharma GmbH
Transient hyperglycaemia in premature infants
1 trial -
AMINOHIPPURIC ACID, OMNIPAQUE 300 mg I/ml soluzione iniettabile, Felzartamab
Istituto Gentili S.r.l.
Membranous nephropathy
1 trial -
AMO959, ENZALUTAMIDE, Enzalutamide, Prednison 5 mg GALENยฎ Tabletten, -, DEGARELIX, RELUGOLIX, Prednison acis 5 mg, Pluvicto 1 000 MBq/mL solution for injection/infusion, ABIRATERONE, Abiraterone, PIFLUFOLASTAT (18F), AMO959, GOZETOTIDE, DEGARELIX
Novartis Pharmaceuticals
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
1 trial -
AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP
Pari Pharma GmbH
Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission
1 trial -
AN OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE SAFETY AND EFFICACY IN PARTICIPANTS TREATED WITH CRN04894
Lacuna Pharma Pty Ltd
CONGENITAL ADRENAL HYPERPLASIA
1 trial -
AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-102 TREATMENT ON DISEASE PROGRESSION PRIOR TO HUMAN STEM CELL TRANSPLANT (HSCT)
Minoryx Therapeutics S.L.
CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD)
1 trial -
ANAKINRA
AXIM BIOTECHNOLOGIES, INC.
Hyperinflammation, Sepsis
1 trial -
ANEB-001
Anebulo Pharmaceuticals
Acute Cannabinoid Intoxication
1 trial -
AP02 High, AP02 Low, AP02 Placebo
Lacuna Pharma Pty Ltd
Idiopathic Pulmonary Fibrosis (IPF)
1 trial -
AP31969, AP31969, The placebo tablets contain the same excipient as in the active IMP, but without AP31969. All tablet strengths containing AP31969 as well as placebo tablets are visually identical., AP31969, AP31969
Lacuna Pharma Pty Ltd
Atrial fibrillation
1 trial -
APD811
United Therapeutics Europe Ltd
Pulmonary Arterial Hypertension
1 trial -
APL-3007, pegcetacoplan (APL-2)
Apellis Europe B.V.
Geographic Atrophy Secondary to Age-related Macular Degeneration
1 trial -
APR-246
Aprea Therapeutics
Myelodysplastic Syndrome With Gene Mutation
1 trial -
APREPITANT, IDARUBICIN HYDROCHLORIDE, LEVOCARNITINE, CYCLOPHOSPHAMIDE, GRANISETRON, SALBUTAMOL, GANCICLOVIR, AMPHOTERICIN B, ALLOPURINOL, DARZALEX 1800 mg solution for injection, HUMAN FIBRINOGEN, CYTARABINE, DEXAMETHASONE SODIUM PHOSPHATE, VINCRISTINE SULFATE, PARACETAMOL, MONTELUKAST, FILGRASTIM, CYTARABINE, LEVOFLOXACIN, RASBURICASE, METHOTREXATE, HYDROCORTISONE, FOSCARNET, METHYLPREDNISOLONE SODIUM SUCCINATE, LENOGRASTIM, PEGASPARGASE, DEXAMETHASONE SODIUM PHOSPHATE, MICAFUNGIN, ACICLOVIR, CHLORPHENAMIN
Fondazione Telethon ETS
Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)
1 trial -
ARB-001467
Arbutus Biopharma Corp
Hepatitis B, Chronic
1 trial -
ARC-520 Injection
Arrowhead Pharmaceuticals Ireland Limited
Hepatitis B
2 trials -
ARC-520 Injection
Arrowhead Pharmaceuticals Ireland Limited
Chronic Hepatitis B
1 trial -
ARC-AAT Injection
Arrowhead Pharmaceuticals Ireland Limited
Alpha-1 Antitrypsin Deficiency
2 trials -
ARI-0001, YESCARTA 0.4 โ 2 x 10e8 cells dispersion for infusion
Disc Medicine
relapsed/refractory Non-Hodgkin Lymphoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources